Best Dividend Aristocrats this March 2026

PepsiCo (PEP) stands out as a consumer staples leader with a solid dividend growth strategy, making it a reliable choice for income-focused investors. Currently, it offers a dividend yield of 3.45% and has delivered impressive returns of 27.70% over the past five years. Analysts maintain a favorable outlook, with a median price target of $165.00, reflecting strong confidence in its long-term stability despite recent sales challenges.

PepsiCo (PEP) offers a solid dividend yield of 3.36%, making it a relatively safe investment for income-focused investors.

PepsiCo (NASDAQ: PEP) is near a four-year low due to stagnant sales growth and weak consumer spending.

Amcor (AMCR) presents itself as an undervalued Dividend Aristocrat, making it an appealing choice for investors seeking consistent income from financially healthy companies. With a notable dividend yield of 5.27%, it has faced challenges, reflected in a 1-year return of -6.87% and a 5-year return of -17.75%. Analysts remain optimistic, with 83% recommending a buy and a median 12-month price target of $14.25.

33% of analysts recommend Amcor Plc (AMCR) as a Strong Buy, 50% as a Buy, and 17% suggest holding, with no analysts advising a Sell.

Amcor PLC (AMCR) is trading near its 52-week high and above its 200-day moving average, with a recent price increase of $0.19, or 0.39%.

Amcor is projected to grow earnings by 19.8% and revenue by 4.8% annually, with an expected EPS growth of 21.8% and a return on equity forecasted at 17.8% in three years.

Kimberly-Clark (KMB) stands out as a Dividend King, boasting a robust portfolio of brands like Huggies and Kleenex. With a dividend yield of 4.84%, this stock targets investors seeking reliable income and mid-single-digit growth. However, recent challenges have led to a downward revision of earnings estimates for 2025 and 2026, and analysts maintain a cautious outlook, with a median price target of $115.00.

Kimberly-Clark (KMB) has revised its earnings per share (EPS) estimates downward for fiscal 2025 and 2026, with a consensus rating of Hold from 12 analysts.

Based on our Discounted Cash Flow (DCF) analysis, Kimberly-Clark is currently undervalued by 40.6%, with a recent share price of $109.90.

Air Products and Chemicals (APD) stands out as a reliable industrial Dividend Aristocrat, trading below its fair value while consistently increasing dividends. With a current dividend yield of approximately 2.63%, this stock appeals to investors seeking dependable income from financially healthy companies. Analysts maintain a neutral consensus on APD, with a median price target of $295, suggesting potential for growth alongside its solid performance in the dividend space.

APD stock has a neutral consensus from 30 Wall Street analysts, with a median price target of $295, suggesting a potential upside of 5.2% from its current price of $280.30.

APD stock is declining due to weaker demand in key markets, particularly for helium and from manufacturing customers in certain regions, as reported by Reuters.

Clorox (CLX) stands out as a top-rated Dividend Aristocrat, recognized for its reliable dividend growth, despite facing challenges such as muted category growth and recent ERP system implementation effects. Currently, it offers an attractive dividend yield of 4.09% while trading below its fair value estimate, making it a compelling option for income-focused investors. Analysts have a consensus rating of Hold, with a median 12-month price target of $121.00, indicating cautious optimism amidst recent performance declines.

Clorox is experiencing sales pressure due to slow category growth and challenges from its ERP system implementation, which caused temporary stock shortages and market share losses.

Clorox (CLX) has a consensus rating of Hold from 11 analysts, with 9% recommending Strong Buy, 0% Buy, 64% Hold, 18% Sell, and 9% Strong Sell.

The median price target for CLX is $121.00, indicating a potential downside of 4.8% from its current trading price of $127.16, with a neutral consensus rating of Hold.

FactSet Research (FDS) is a newly added financial data firm boasting a solid history of dividend payments, making it an attractive option for income-focused investors. Despite a current dividend yield of 2.03% and a challenging performance history, with a one-year return of -51.35% and a five-year return of -27.84%, analysts have set a median price target of $295.00, suggesting potential for recovery. With 60% of analysts recommending a Hold and a B+ rating overall, it may warrant consideration for those looking to invest in undervalued stocks with strong dividend potential.

FDS has a consensus rating of Hold from 10 analysts, with 10% recommending a Strong Buy, 60% suggesting Hold, and 30% advising Sell.

FDS is currently considered undervalued, with a forward PE ratio of 15.98 compared to its five-year average of 26.97, indicating a fair price range of $289.99 to $362.87.

Becton Dickinson (BDX) stands out as a high-quality Dividend Aristocrat, boasting a robust economic moat and a long track record of increasing dividends for 50 consecutive years. With a dividend yield of approximately 2.02% and an impressive one-year return of 23.39%, it remains an attractive choice for income-focused investors. Analysts are optimistic, with a consensus rating of Buy and a median 12-month price target of $202, suggesting potential upside ahead.

BDX has a consensus rating of 'Buy' from 10 analysts, with 30% recommending a 'Strong Buy', 20% a 'Buy', and 50% suggesting 'Hold'.

Analysts project a target price range for BDX between $157.00 and $225.00, with an average target of $195.38, indicating a potential upside of 11.08%.

Becton Dickinson is a dividend king, having raised its dividend for 50 consecutive years.

The stock is declining due to lowered profit guidance, despite a recent revenue beat, indicating potential margin pressures or increased operational costs.

West Pharmaceutical (WST) stands out as a highly-rated investment among Dividend Aristocrats, noted for its solid valuation and competitive edge. With a modest dividend yield of approximately 0.35%, the stock is projected to deliver year-over-year earnings growth of 7.3% in the current fiscal year, appealing to investors seeking reliable income from financially healthy companies.

WST is rated #2 (Buy) on the Zacks Rank with a Momentum Style Score of B, indicating strong potential as shares have risen 2% in the past month.

WST forecasts a year-over-year earnings growth of 7.3% for the current fiscal year, with recent upward revisions from five analysts increasing the Zacks Consensus Estimate to $7.82 per share.

For full-year 2026, West Pharma expects net sales between $3.215 billion and $3.275 billion, with reported growth projected at 4.6% to 6.5%.

Seven analysts have a consensus rating of Buy for WST, with 43% recommending a Strong Buy and none advising a Sell.